PMID: 11903511Mar 21, 2002Paper

5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study

Fundamental & Clinical Pharmacology
A VermesJacob Dankert

Abstract

The aim of this study is to investigate whether fluorouracil (5-FU) could be responsible for bone-marrow depression occurring in fluorocytosine (5-FC) treated patients. Six 5-FC treated patients were included in this pilot study. Toxicity was monitored by means of thrombocyte and leucocyte counts. 5-FC and 5-FU serum levels were measured using a high-performance liquid chromatography (HPLC) assay that allows simultaneous determination of both compounds. The amounts of 5-FU in the 34 available serum samples remained below the limit of quantitation (< 0.05 mg/L), whereas 5-FC levels could be detected in all samples. Instead, low levels of the 5-FU catabolite alpha-fluoro-beta-alanine (FBAL) were detected in several of the investigated serum samples. In case of three patients thrombocyte counts remained within the normal range during 5-FC treatment, whereas one patient developed thrombocytopenia (50 x 10(9) thrombocytes/L) during therapy. Furthermore, one patient developed leucocytopenia (2.6 x 10(9) leucocytes/L) during 5-FC therapy, whereas the remaining five patients were suffering from leucocytosis prior to 5-FC therapy. In conclusion, we found nondetectable 5-FU serum concentrations (< 0.05 mg/L) in ICU patients treated with ...Continue Reading

References

Mar 1, 1977·Annals of Internal Medicine·J E Bennet
Mar 1, 1978·Biochemical Pharmacology·R B DiasioC E Myers
Jul 19, 1979·The New England Journal of Medicine·J E BennettD W Alling
Feb 1, 1977·Antimicrobial Agents and Chemotherapy·C A Kauffman, P T Frame
Oct 1, 1975·The Journal of Infectious Diseases·J P UtzS Shadomy
Dec 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P Francis, T J Walsh
Jan 1, 1986·Antimicrobial Agents and Chemotherapy·B E HarrisR B Diasio
Aug 1, 1974·The Journal of Infectious Diseases·T EilardP Wahlén
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·A R Waldorf, A Polak
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-analysis Group In CancerE Levy
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-Analysis Group In CancerP Thirion
Apr 24, 1999·Pharmacy World & Science : PWS·A VermesH J Guchelaar
Feb 15, 2000·Chemotherapy·A VermesH J Guchelaar
Aug 14, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·A B Van KuilenburgA H Van Gennip

❮ Previous
Next ❯

Citations

Sep 17, 2013·Expert Opinion on Drug Metabolism & Toxicology·Mi Jeong KangHye Gwang Jeong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.